What the Mounjaro studies really found — and what they didn't

The biggest misconception: the trial results are not a personal prediction

Ask most people what the Mounjaro studies showed and they'll quote the headline: you lose about a fifth of your body weight. That figure is real. It comes from the SURMOUNT-1 trial published in the New England Journal of Medicine, where adults receiving 15mg tirzepatide lost an average of around 20–21% of starting body weight over 72 weeks alongside a reduced-calorie diet and increased activity. Some analyses put the upper end of that range at roughly 22.5%.

What the headline skips: that is an average across 2,539 participants. Individuals varied considerably. Some lost substantially more; some lost less. Age, starting weight, metabolic health, how consistently people took the medicine and engaged with lifestyle changes, all of it influenced outcomes. Citing a clinical trial average as a personal forecast is the error that shapes most of the unrealistic expectations people bring to an initial consultation.

The studies also tell you what conditions participants were in. SURMOUNT-1 enrolled adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition, without type 2 diabetes. If your situation differs, a different part of the evidence base may be more relevant, or the prescriber weighs the transferability of the data.

What the studies on tirzepatide actually measured

The SURMOUNT programme covered more than weight loss in healthy-weight adults. SURMOUNT-2 looked at adults with type 2 diabetes. SURMOUNT-3 and SURMOUNT-4 examined intensive lifestyle support phases before and during treatment. The SUMMIT trial investigated tirzepatide in adults with heart failure and obesity, expanding the picture well beyond straightforward weight management.

Across the programme, the most consistent finding is that tirzepatide's dual activation of GIP and GLP-1 receptors produces appetite reduction and slowed gastric emptying, translating into meaningful caloric reduction that people sustain over months rather than weeks. Blood glucose markers, blood pressure and lipid profiles also improved in many participants, which is part of why NICE recommended tirzepatide for adults with a BMI of 35 or above alongside at least one weight-related comorbidity.

The studies are also where the side-effect picture comes from. GI effects (nausea, diarrhoea, constipation, reflux) were the most frequently reported, most commonly appearing at the start of treatment or after a dose step. Serious adverse events were uncommon but documented; the MHRA maintains post-approval surveillance precisely because trial populations, however large, cannot capture every real-world scenario. Keeping your Mounjaro pen in the fridge door is a small daily detail; checking the patient information leaflet each time you take a dose is how you stay on top of what the evidence says matters most practically.

The head-to-head comparison with semaglutide

For a long time, the GLP-1 medicine most people knew about was Wegovy (semaglutide). Studies on tirzepatide existed in parallel but not in direct comparison, until SURMOUNT-5. That 72-week open-label trial enrolled 751 adults with obesity and no diabetes and ran tirzepatide against semaglutide 2.4mg directly. Tirzepatide produced greater average weight loss. The results were published in the New England Journal of Medicine in 2025 and informed the NICE technology appraisal TA1026, which acknowledged that indirect comparisons also favour tirzepatide.

This matters for the conversation about which medicine suits which person. Semaglutide at its newer 7.2mg maintenance dose narrows the gap somewhat. But the head-to-head data (rather than cross-trial comparisons, which methodologists treat with caution) is one of the more definitive pieces of evidence currently available in this field. You can read more about how the most recent tirzepatide studies developed the evidence base through 2025.

What the studies don't tell you, and why that changes how to read them

Clinical trials are controlled environments. Participants attend regular check-ins, receive dietary coaching, and know they are being observed. Real-world outcomes are typically more variable. If you want to see how that plays out closer to home, our Mounjaro service in Coventry is one example of how the evidence translates into day-to-day clinical practice. The long-term Mounjaro evidence also has a horizon: most trials ran to 72 weeks, and weight regain data after stopping treatment is accumulating but not yet as extensive as the treatment-phase data. NICE's own guidance acknowledges the evidence for sustained outcomes beyond trial periods is still developing.

None of that makes the trial data unreliable. It makes it what it is: the best available evidence from well-designed studies, applied to a clinical decision that still requires an individual assessment. Cost is part of that decision too, the full picture of Mounjaro pricing in the UK has shifted considerably since Eli Lilly revised its list price in September 2025.

If you're trying to understand whether the evidence applies to your situation, speaking to a prescriber who has read the primary studies is the only way to get an answer that accounts for your health, your history and your goals. Our prescribers review each consultation personally, and if you'd like to go deeper into the science before that conversation, our guide to the Mounjaro study evidence is a good place to start. Speak to our prescribers through a free consultation and get a clinical view grounded in the actual evidence.